[1]
|
单冬勇, 成树林, 马邺晨, 等. 上皮性卵巢癌血清中肿瘤标志物水平及其临床意义(英文) [J]. 中南大学学报(医学版), 2023, 48(7): 1039-1049.
|
[2]
|
Saner, F.A.M., Ruggeri, G., Siegenthaler, F., Wampfler, J., Imboden, S. and Mueller, M.D. (2023) Change of Fagotti Score Is Associated with Outcome after Neoadjuvant Chemotherapy for Ovari-an Cancer. International Journal of Gynecological Cancer, 33, 1595-1601. https://doi.org/10.1136/ijgc-2023-004540
|
[3]
|
朱秀红, 毛翠玉, 张燕, 等. 卵巢癌新辅助化疗的研究进展[J]. 现代妇产科进展, 2023, 32(11): 865-869.
|
[4]
|
付小玲, 郭哲, 唐旭. 晚期卵巢癌新辅助化疗中应用紫杉醇联合铂类改良剂量密集型疗法对患者卵巢血流参数、肿瘤标志物水平、生存情况的影响[J]. 实用癌症杂志, 2023, 38(4): 686-688, 693.
|
[5]
|
Jakob, D., Schmoor, C., Reuten, R., Frevert, M.L., Dannehl, D., Jansen, L., Hermann, S., Jung-mann, P., Hartkopf, A.D., Juhasz-Böss, I. and Taran, F.A. (2023) Characteristics, Treatment Patterns and Survival of In-ternational Federation of Gynecology and Obstetrics Stage IV Epithelial Ovarian Cancer—A Population-Based Study. Cancers, 15, Article 5676.
https://doi.org/10.3390/cancers15235676
|
[6]
|
卢淮武, 叶栋栋, 吴斌, 等. 《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(1): 58-67.
|
[7]
|
袁航, 张师前, 李小平, 等. 晚期上皮性卵巢癌新辅助化疗指征的快速指南(2021年版) [J]. 中国实用妇科与产科杂志, 2021, 37(4): 444-448.
|
[8]
|
Griffiths, C.T. (1975) Surgical Resection of Tumor Bulk in the Primary Treatment of Ovarian Car-cinoma. National Cancer Institute Monograph, 42, 101-104.
|
[9]
|
Bryant, A., Hiu, S., Kunonga, P.T., Gajjar, K., Craig, D., Vale, L., Winter-Roach, B.A., Elattar, A. and Naik, R. (2022) Impact of Residual Disease as a Prognostic Factor for Survival in Women with Advanced Epithelial Ovarian Cancer after Primary Surgery. The Cochrane Database of System-atic Reviews, 9, CD015048.
https://doi.org/10.1002/14651858.CD015048.pub2
|
[10]
|
卢淮武, 许妙纯, 张钰豪, 等. 《2021 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(4): 457-466.
|
[11]
|
Colombo, N., Sessa, C., Bois, A.D., Ledermann, J., McCluggage, W.G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., Querleu, D. and ESMO-ESGO Ovarian Cancer Consensus Conference Working Group (2019) ESMO-ESGO Consensus Confer-ence Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. International Journal of Gynecological Cancer, 29, 728-760. https://doi.org/10.1136/ijgc-2019-000308
|
[12]
|
Armstrong, D.K., Alvarez, R.D., Bakkum-Gamez, J.N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.M., Cristea, M., DeRosa, M., Eisenhauer, E.L., Gershenson, D.M., Gray, H.J., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G.E., Leath, C.., Liu, J., Mahdi, H., Engh, A.M., et al. (2021) Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehen-sive Cancer Network, 19, 191-226.
https://doi.org/10.6004/jnccn.2021.0007
|
[13]
|
Vergote, I., Tropé, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., Verheijen, R.H., van der Burg, M.E., Lacave, A.J., Panici, P.B., Kenter, G.G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G.C., Pecorelli, S., Reed, N.S., European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group and NCIC Clinical Trials Group (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. The New England Journal of Medicine, 363, 943-953. https://doi.org/10.1056/NEJMoa0908806
|
[14]
|
王泽华, 蔡晶. 妇科肿瘤新辅助化疗: 用好则好用[J]. 中国实用妇科与产科杂志, 2023, 39(7): 673-676.
|
[15]
|
Fagotti, A., Ferrandina, G., Vizzielli, G., Fanfani, F., Gallotta, V., Chian-tera, V., Costantini, B., Margariti, P.A., Gueli Alletti, S., Cosentino, F., Tortorella, L. and Scambia, G. (2016) Phase III Randomised Clinical Trial Comparing Primary Surgery versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovar-ian Cancer with High Tumour Load (SCORPION Trial): Final Analysis of Peri-Operative Outcome. European Journal of Cancer, 59, 22-33.
https://doi.org/10.1016/j.ejca.2016.01.017
|
[16]
|
Onda, T., Satoh, T., Saito, T., Kasamatsu, T., Nakanishi, T., Naka-mura, K., Wakabayashi, M., Takehara, K., Saito, M., Ushijima, K., Kobayashi, H., Kawana, K., Yokota, H., Takano, M., Takeshima, N., Watanabe, Y., Yaegashi, N., Konishi, I., Kamura, T., Yoshikawa, H. and Japan Clinical Oncology Group (2016) Comparison of Treatment Invasiveness between Upfront Debulking Surgery versus Interval Debulking Surgery following Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal, and Peritoneal Cancers in a Phase III Randomised Trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer, 64, 22-31. https://doi.org/10.1016/j.ejca.2016.05.017
|
[17]
|
Tzanis, A.A., Iavazzo, C., Hadjivasilis, A., Tsouvali, H., Antoniou, G.Α. and Antoniou, S.A. (2022) Neoadjuvant Chemotherapy versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis. Oncology Reviews, 16, Ar-ticle 10605.
https://doi.org/10.3389/or.2022.10605
|
[18]
|
Coleridge, S.L., Bryant, A., Kehoe, S. and Morrison, J. (2021) Chem-otherapy versus Surgery for Initial Treatment in Advanced Ovarian Epithelial Cancer. The Cochrane Database of Sys-tematic Reviews, 2, CD005343.
https://doi.org/10.1002/14651858.CD005343.pub5
|
[19]
|
Coleridge, S.L., Bryant, A., Kehoe, S. and Morrison, J. (2021) Neoadjuvant Chemotherapy before Surgery versus Surgery Followed by Chemotherapy for Initial Treatment in Advanced Ovarian Epithelial Cancer. The Cochrane Database of Systematic Reviews, 7, CD005343. https://doi.org/10.1002/14651858.CD005343.pub6
|
[20]
|
Bartels, H.C., Rogers, A.C., McSharry, V., McVey, R., Walsh, T., O’Brien, D., Boyd, W.D. and Brennan, D.J. (2019) A Meta-Analysis of Morbidity and Mortality in Primary Cytoreductive Surgery Compared to Neoadjuvant Chemotherapy in Advanced Ovarian Malignancy. Gynecologic Oncol-ogy, 154, 622-630.
https://doi.org/10.1016/j.ygyno.2019.07.011
|
[21]
|
牛星燕, 张冬萍, 李飞霞, 等. 卵巢恶性肿瘤化疗研究进展[J]. 国际妇产科学杂志, 2020, 47(2): 125-128.
|
[22]
|
Coada, C.A., Dondi, G., Ravegnini, G., Di Costanzo, S., Tesei, M., Fiuzzi, E., Di Stanislao, M., Giunchi, S., Zamagni, C., Bovicelli, A., Hrelia, P., Angelini, S., De Iaco, P. and Perrone, A.M. (2023) Optimal Number of Neoadjuvant Chemotherapy Cycles Prior to Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis of Progression-Free Survival and Overall Survival. Journal of Gynecologic Oncology, 34, e82. https://doi.org/10.3802/jgo.2023.34.e82
|
[23]
|
Marchetti, C., Rosati, A., De Felice, F., Boccia, S.M., Vertechy, L., Pavone, M., Palluzzi, E., Scambia, G. and Fagotti, A. (2021) Optimizing the Number of Cycles of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Carcinoma: A Propensity-Score Matching Analysis. Gynecologic Oncology, 163, 29-35.
https://doi.org/10.1016/j.ygyno.2021.07.025
|
[24]
|
Kumari, A., Thakur, M., Saha, S.C., Suri, V., Prasad, G.R.V., Patel, F.D. and Radhika, S. (2021) To Compare the Optimal Cytoreduction Rate in Advanced Epithelial Ovarian Cancer Stage III/IV after 3 versus 6 Cycles of Neoadjuvant Chemotherapy. Journal of Obstetrics and Gynaecology, 41, 616-620. https://doi.org/10.1080/01443615.2020.1787967
|
[25]
|
Perrone, A.M., Coada, C.A., Ravegnini, G., De Leo, A., Damiano, G., De Crescenzo, E., Tesei, M., Di Costanzo, S., Genovesi, L., Rubino, D., Zamagni, C. and De Iaco, P. (2023) Post-Operative Residual Disease and Number of Cycles of Neoadjuvant Chemotherapy in Advanced Ep-ithelial Ovarian Carcinoma. International Journal of Gynecological Cancer, 33, 1270-1278. https://doi.org/10.1136/ijgc-2022-004249
|
[26]
|
Pieterse, Z., Amaya-Padilla, M.A., Singomat, T., Binju, M., Madjid, B.D., Yu, Y. and Kaur, P. (2019) Ovarian Cancer Stem Cells and Their Role in Drug Resistance. The International Journal of Biochemistry & Cell Biology, 106, 117-126.
https://doi.org/10.1016/j.biocel.2018.11.012
|
[27]
|
Leary, A., Cowan, R., Chi, D., Kehoe, S. and Nankivell, M. (2016) Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues… American Society of Clinical Oncology Educational Book, 35, 153-162. https://doi.org/10.1200/EDBK_160624
|
[28]
|
Liu, J., Jiao, X. and Gao, Q. (2020) Neoadjuvant Chemotherapy-Related Platinum Resistance in Ovarian Cancer. Drug Discov-ery Today, 25, 1232-1238. https://doi.org/10.1016/j.drudis.2020.04.015
|
[29]
|
Vergote, I., Amant, F., Kristensen, G., Ehlen, T., Reed, N.S. and Casado, A. (2011) Primary Surgery or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer. European Journal of Cancer, 47, S88-S92. https://doi.org/10.1016/S0959-8049(11)70152-6
|
[30]
|
Wu, J., Zhou, T., Wang, Y., Jiang, Y. and Wang, Y. (2021) Mechanisms and Advances in Anti-Ovarian Cancer with Natural Plants Component. Molecules, 26, Article 5949. https://doi.org/10.3390/molecules26195949
|
[31]
|
Margioula-Siarkou, C., Petousis, S., Papanikolaou, A., Gullo, G., Margioula-Siarkou, G., Laganà, A.S., Dinas, K. and Guyon, F. (2022) Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer—State of the Art. Przeglad Menopauzalny, 21, 272-275. https://doi.org/10.5114/pm.2022.124018
|
[32]
|
Rouzier, R., Gouy, S., Selle, F., Lambaudie, E., Floquet, A., Four-chotte, V., Pomel, C., Colombo, P.E., Kalbacher, E., Martin-Francoise, S., Fauvet, R., Follana, P., Lesoin, A., Lecuru, F., Ghazi, Y., Dupin, J., Chereau, E., Zohar, S., Cottu, P. and Joly, F. (2017) Efficacy and Safety of Bevaci-zumab-Containing Neoadjuvant Therapy followed by Interval Debulking Surgery in Advanced Ovarian Cancer: Results from the ANTHALYA Trial. European Journal of Cancer, 70, 133-142. https://doi.org/10.1016/j.ejca.2016.09.036
|
[33]
|
Garcia Garcia, Y., de Juan Ferré, A., Mendiola, C., Barreti-na-Ginesta, M.P., Gaba Garcia, L., Santaballa Bertrán, A., Bover Barcelo, I., Gil-Martin, M., Manzano, A., Rubio Pérez, M.J., Romeo Marin, M., Arqueros Núñez, C., García-Martínez, E. and Gonzalez Martin, A. (2019) Efficacy and Safety Results from GEICO 1205, a Randomized Phase II Trial of Neoadjuvant Chemotherapy with or without Bevacizumab for Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 29, 1050-1056. https://doi.org/10.1136/ijgc-2019-000256
|
[34]
|
Nag, S., Aggarwal, S., Rauthan, A. and Warrier, N. (2022) Mainte-nance Therapy for Newly Diagnosed Epithelial Ovarian Cancer—A Review. Journal of Ovarian Research, 15, Article No. 88.
https://doi.org/10.1186/s13048-022-01020-1
|
[35]
|
Goh, J.C.H., Gourley, C., Tan, D.S.P., Nogueira-Rodrigues, A., Elghazaly, H., Edy Pierre, M., Giornelli, G., Kim, B.G., Morales-Vasquez, F. and Tyulyandina, A. (2022) Optimizing Treatment Selection and Sequencing Decisions for First-Line Maintenance Therapy of Newly Diagnosed Advanced Ovarian Cancer. Gynecologic Oncology Reports, 42, Article ID: 101028. https://doi.org/10.1016/j.gore.2022.101028
|
[36]
|
Banerjee, S., Moore, K.N., Colombo, N., Scambia, G., Kim, B.G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Oza, A., Gonzá-lez-Martín, A., Aghajanian, C., Bradley, W.H., Holmes, E., Lowe, E.S. and Di Silvestro, P. (2021) Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation (SOLO1/GOG 3004): 5-Year Follow-Up of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 22, 1721-1731. https://doi.org/10.1016/S1470-2045(21)00531-3
|
[37]
|
Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast (2021) Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatinum in Patients with HER2-Negative Breast Cancer and Homologous Recombination Deficiency (GeparOLA Study). Annals of Oncology, 32, 49-57.
https://doi.org/10.1016/j.annonc.2020.10.471
|